alirocumab
Sign in to saveAlso known as REGN727, SAR-236553, SAR236553
Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2015
- Admin. routes
- parenteral
- Indications
- Disorder of lipid metabolism, Hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease
via ChEMBL · EBI
Research
1,255 papers- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.JAMA · 2022
- Alirocumab: Pediatric First Approval.Paediatric drugs · 2024
- Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.JAMA pediatrics · 2024
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.Journal of the American College of Cardiology · 2020
- Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.The New England journal of medicine · 2015
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 5 more facts
- World Health Organisation international non-proprietary name
- alirocumab
- defined daily dose
- 5.4
- chemical formula
- C₆₄₇₂H₉₉₉₆N₁₇₃₆O₂₀₃₂S₄₂
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
via Wikidata · CC0
~12 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Chemistry
- History
- Society and culture
- Names
- References
Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.
Common side effects include nasopharyngitis (cold), injection site reactions, and influenza.
Excerpted from Wikipedia’s “alirocumab” article, available under the CC BY-SA 4.0 licence.